Phase three clinical trial of India’s own dengue vaccine, DengiAll, initiated – Times of India
The first-ever phase three clinical trial for India’s indigenous tetravalent dengue vaccine, DengiALL has been initiated. DengiALL has been developed by Panacea Biotec. Currently, there is no antiviral treatment or licensed vaccine against dengue in India.The phase three clinical trial will be conducted across 19 sites in 18 states and union territories, involving more than…